Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 9/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437198 | 0.84 | NTMT1 (0.41) | DPP4F2 | |
| SCHEMBL9577364 | 0.83 | DPP4 (0.41) | DPP4F2 | |
| SCHEMBL15524993 | 0.83 | DPP4 (0.41) | DPP4F2 | |
| SCHEMBL7853147 | 0.83 | DPP4 (0.41) | DPP4F2 | |
| SCHEMBL15474347 | 0.83 | DPP4 (0.50) | NPSR1DPP4POLBTSHRF2 | |
| SCHEMBL17706045 | 0.83 | DPP4 (0.47) | NPSR1DPP4FKBP1AF2 | |
| SCHEMBL10590044 | 0.82 | F2 (0.37) | NPSR1DPP4F2PREPFAP | |
| SCHEMBL20729857 | 0.82 | DPP4 (0.48) | NPSR1DPP4F2 | |
| SCHEMBL29556306 | 0.81 | BDKRB2 (0.39) | DPP4 | |
| SCHEMBL22209356 | 0.80 | MALT1 (0.41) | DPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | NPSR1 4254/4885DPP4 532/4885FKBP1A 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.